Avacta Group

Activities: Research & Development Analysis Pharmaceutical

Trending Articles

  1. Beneo presents its taste-boosting excipient, galenIQ at CPHI 2024 galenIQ is designed to improve the flavour of oral solid dosage (OSD) forms for more patient-centric pharmaceuticals
  2. Merck's MilliporeSigma cuts the ribbon on €290m US biosafety and analytical facility The site will host biosafety testing, analytical development and cell banking manufacturing services
  3. Seppic launches surfactant excipient for the optimisation of biological formulations The ingredient is compatible with sensitive biologics, and aims to stabilise injectables for improved bioavailability, efficacy and shelf life
  4. Strides Group launches CDMO OneSource Specialty Pharma at CPHI Milan The newly integrated CDMO primarily specialises in the manufacture of biologics, drug-device combos and gelatin capsules
  5. Johnson & Johnson completes V-Wave acquisition to support patients with heart failure The strategic acquisition will bolster the pharma giant's MedTech offerings for patients with cardiovascular disease

Upcoming event

ISCC

15-18 October 2024 | Conference | Milan, Italy See all

Related Content

Research & Development

Avacta achieves milestone in AffyXell joint venture

The second milestone will result in an increase in Avacta’s shareholding in AffyXell, which currently stands at 19%
Research & Development

AffyXell expands partnership with GenScript ProBio

As part of the strategic alliance, GenScript has committed to take an equity position in AffyXell at a future funding round
Finance

Avacta appoints Non-Executive Director to board

Christina Coughlin previously served as CMO to Rubius Therapeutics, where she led the clinical development, translational medicine and regulatory efforts for the company
Analysis

Avacta provides update on its antigen test for Omicron

The company has taken the decision to pause sales of the AffiDX antigen test while it replaces the antibody in the product to ensure its performance with the Omicron variant matches that of the previous mutations
Finance

Astrea Bioseparations invests in infrastructure in UK and Singapore

The company has expanded its R&D facility in Cambridge, UK, and registered a branch office in Singapore
Finance

Avacta appoints Chief Scientific Officer of therapeutics division

Dr Alastair Smith, CEO of Avacta Group, commented: “We are delighted to have Fiona McLaughlin join us as Chief Scientific Officer of our therapeutics division
Finance

Avacta appoints Dr Mark Goldberg as Non-Executive Director

Goldberg currently serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Walden Biosciences, and Blueprint Medicines
Subscribe now